Akebia Therapeutics, Inc. AKBA
- Market cap
- $254.7M
- P/E
- 0.0×
Follow AKBA
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7.00 | 8.58 | 5.20 | 2.99 | 2.09 | 2.20 | 0.24 | 0.49 | 0.80 | 1.45 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| 12.74 | 20.25 | 15.86 | 9.30 | 13.71 | 5.14 | 2.93 | 1.84 | 2.48 | 4.08 |
High Price
|
|||
| 90 | 114 | 325 | 360 | 380 | 426 | 205 | 167 | 181 | 194 |
Employees
|
|||
| 0 | 2 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 |
Revenue/Emp
|
|||
| 2 | 181 | 208 | 335 | 295 | 212 | 292 | 195 | 160 | 236 |
Revenue
|
|||
| 100.00% | 100.00% | 96.26% | 56.62% | 38.21% | 28.81% | 70.74% | 61.90% | 60.56% | 83.29% |
Gross Margin
|
|||
| (136) | (74) | (172) | (286) | (385) | (282) | (94) | (52) | (69) | (4) |
EBT
|
|||
| (8,843.45%) | (40.65%) | (82.76%) | (85.46%) | (130.61%) | (133.25%) | (32.22%) | (26.68%) | (43.33%) | (1.58%) |
EBT Margin
|
|||
| (136) | (74) | (144) | (280) | (385) | (282) | (94) | (52) | (69) | (5) |
Net Income
|
|||
| 1 | 1 | 1 | 38 | 149 | 38 | 38 | 38 | 38 | 1 |
Depreciation
|
|||
| 0.04 | 4.17 | 3.58 | 2.83 | 2.13 | 1.28 | 1.60 | 1.04 | 0.76 | 0.92 |
Revenue/Sh
|
|||
| (3.60) | (1.77) | (2.47) | (2.36) | (2.77) | (1.70) | (0.51) | (0.28) | (0.33) | (0.02) |
Earnings/Sh
|
|||
| 1.54 | (1.29) | (1.68) | (2.17) | (0.80) | (1.52) | (0.40) | (0.12) | (0.19) | 0.26 |
Cash Flow/Sh
|
|||
| (0.07) | (0.04) | (0.03) | (0.06) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex/Sh
|
|||
| 1.46 | (1.33) | (1.71) | (2.23) | (0.80) | (1.52) | (0.40) | (0.12) | (0.19) | 0.26 |
Free CF/Sh
|
|||
| 1.81 | 2.82 | 10.96 | 3.33 | 1.79 | 0.45 | 0.03 | (0.16) | (0.23) | 0.13 |
Book Value/Sh
|
|||
| 38 | 44 | 58 | 118 | 138 | 166 | 183 | 187 | 211 | 257 |
Shares
|
|||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
PE Ratio
|
|||
| 0.00 | 3.59 | 1.54 | 2.23 | 1.32 | 1.77 | 0.39 | 1.22 | 2.50 | 1.75 |
PS Ratio
|
|||
| 5.81 | 5.31 | 0.50 | 1.90 | 1.57 | 5.07 | 21.67 | 0.00 | 0.00 | 12.70 |
PB Ratio
|
|||
| 0.00 | 1.84 | 1.11 | 2.03 | 0.88 | 1.94 | 0.30 | 1.18 | 2.53 | 1.25 |
EV/Sales
|
|||
| 2.46 | (5.77) | (2.33) | (2.58) | (2.30) | (1.62) | (1.21) | (9.78) | (9.96) | 4.35 |
EV/FCF
|
|||
| 58 | (56) | (97) | (257) | (110) | (253) | (73) | (23) | (41) | 68 |
Op' Cash Flow
|
|||
| (3) | (2) | (2) | (7) | 0 | 0 | 0 | — | 0 | 0 |
Capex
|
|||
| 55 | (58) | (99) | (264) | (111) | (253) | (73) | (23) | (41) | 68 |
FCF
|
|||
| 182 | 217 | 203 | 101 | 184 | 10 | 56 | 18 | 33 | 90 |
Working Cap'
|
|||
| 0 | — | 15 | 81 | 101 | 185 | 66 | 35 | 39 | 48 |
Total Debt
|
|||
| (260) | (318) | (90) | (67) | (127) | 35 | (24) | (8) | (13) | (137) |
Net Debt
|
|||
| 68 | 123 | 636 | 395 | 248 | 74 | 5 | (31) | (49) | 33 |
Sh' Equity
|
|||
| (61.26%) | (22.17%) | (21.10%) | (31.64%) | (54.38%) | (48.07%) | (21.28%) | (17.37%) | (30.02%) | (1.79%) |
ROA
|
|||
| 0.00% | 0.00% | (20.38%) | (54.53%) | (196.30%) | (152.01%) | 0.00% | 0.00% | 0.00% | 0.00% |
ROIC
|
|||
| (136.35%) | (77.27%) | (37.86%) | (54.27%) | (119.82%) | (175.37%) | (237.83%) | 409.60% | 174.03% | 64.49% |
ROE
|
|||
Akebia Therapeutics, Inc. (AKBA) key facts
- Akebia Therapeutics, Inc. (AKBA) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector, listed on Nasdaq.
- Akebia Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $236.2 million, up 47.5% from fiscal 2024.
- Akebia Therapeutics, Inc. reported a net loss of $5.3 million, or a loss of $0.02 per share, for fiscal 2025.
- As of September 25, 2026, AKBA traded at $0.90, a market capitalization of $254.7 million.
- Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 1.1× sales.
- Return on equity was 64.5% and debt-to-equity 1.98.
Akebia Therapeutics, Inc. (AKBA) Latest News
14 Sep
Akebia Therapeutics dosed the first patient in its Phase 2 basket trial of Ebribafusp for rare complement-mediated kidney diseases. Phase 2 trial start for Ebribafusp advances pipeline in rare kidney diseases with moderate effects on future performance and sentiment.
6 Aug
Akebia Therapeutics reported Vafseo surging 60% in Q2 2026 earnings call highlights tied to VOICE. Vafseo 60% sales growth points to major revenue gains and strengthened market position for Akebia.
5 Aug
Akebia Therapeutics posted a Q2 loss and missed revenue estimates. Q2 loss and revenue shortfall points to weaker results that can pressure near-term stock performance.
Akebia Therapeutics reported Q2 results and provided operational updates during its earnings call, covering financial performance, product pipeline progress, and forward guidance. Quarterly earnings releases and call commentary typically move near-term sentiment and trading without altering long-term company trajectory.
Akebia Therapeutics reported second quarter 2026 financial results and business highlights. Quarterly results updates disclose performance metrics that influence near-term investor sentiment without altering long-term strategy.
3 Aug
Akebia Therapeutics initiates Phase 2 basket trial of Ebribafusp, a next-generation complement inhibitor, in rare kidney diseases. Phase 2 trial launch advances pipeline for rare kidney diseases but remains early-stage with limited near-term financial effects.
30 Jun
Akebia Therapeutics strengthens Vafseo patent protection through 2036. Extended Vafseo patent protection to 2036 secures long-term exclusivity and revenue upside.
U.S. Renal Care and Akebia's VOICE Trial interim analysis shows overwhelming statistical evidence of improved safety outcomes for patients treated with Vafseo versus an ESA. Positive VOICE Trial data on Vafseo safety strengthens regulatory and commercial prospects for Akebia's lead product.
10 Jun
Akebia Therapeutics has strengthened its Vafseo (vadadustat) patent portfolio. Patent strengthening improves protection for Vafseo and supports competitive positioning.
4 Jun
Akebia Therapeutics observes rising Vafseo uptake with improving access and pipeline milestones approaching. Rising Vafseo uptake plus access gains and pipeline milestones signal major positive shifts for Akebia's trajectory.
11 May
Analysts are updating estimates for Akebia Therapeutics (NASDAQ:AKBA) following its first-quarter results. Analyst estimate revisions after Q1 results moderately influence AKBA's financial outlook and market sentiment.
8 May
Akebia Therapeutics (AKBA) released Q1 2026 earnings call transcript detailing financial results, operational updates, and forward guidance. Q1 2026 earnings transcript provides critical financial metrics, strategic insights, and outlook shaping AKBA's trajectory and investor sentiment.
Akebia Therapeutics held its Q1 2026 earnings call covering financial results, operational updates, and future outlook for the company. Quarterly earnings call delivers financial and strategic updates that moderately influence near-term stock sentiment and operations.
7 May
Akebia Therapeutics reported Q1 financial results, pipeline advancements including Auryxia sales growth, operational updates, and strategic priorities in its earnings call highlights. Q1 earnings highlights detail financial performance and pipeline progress with moderate influence on investor sentiment and near-term trajectory.
Akebia Therapeutics reported first quarter 2026 financial results, highlighting commercial progress and pipeline developments. Quarterly financial results with commercial and pipeline updates moderately influence financial performance and market sentiment.
4 May
Akebia Therapeutics announced publication of post-hoc win statistics analysis for vadadustat in the Journal of the American Society of Nephrology, demonstrating statistically significant reduction in mortality and hospitalization composite endpoint. Positive post-hoc data on vadadustat's mortality and hospitalization benefits published in JASN bolsters regulatory approval chances and investor sentiment for AKBA.
6 Apr
Akebia Therapeutics (AKBA) narrative shifts after Vafseo revenue reports and protocol updates, signaling improved commercial traction and pipeline progress. Vafseo revenue and protocol updates indicate significant commercialization success and strategic advancements poised to alter AKBA's trajectory and investor sentiment.
2 Apr
Akebia Therapeutics held R&D Day unveiling Vafseo growth and commercialization strategy, Phase 2 trial updates for praliciguat in rare kidney disease, and new pipeline targets addressing unmet needs in kidney health. R&D Day highlights Vafseo expansion, praliciguat Phase 2 progress, and novel kidney targets, driving significant pipeline momentum and investor interest.
19 Mar
Akebia Therapeutics will host a virtual R&D Day on April 2, 2026, highlighting its robust kidney disease pipeline. Announcing an R&D Day to showcase a robust kidney disease pipeline could moderately influence investor sentiment and highlight key product innovation areas.
9 Mar
Akebia Therapeutics detailed its Vafseo commercial expansion, three-times-weekly dosing plans, and kidney disease pipeline advancements at the Leerink Conference. Vafseo commercialization push and pipeline updates represent major strategic initiatives boosting Akebia's growth trajectory and investor confidence.
8 Mar
Akebia Therapeutics (AKBA) story shifts as Vafseo revenue assumptions reset, altering expectations for future performance. Vafseo revenue assumption reset represents a significant shift in market dynamics and investor sentiment for Akebia Therapeutics.
27 Feb
Akebia Therapeutics, Inc. (AKBA) released Q4 2025 earnings call summary highlighting financial results, operational updates, and forward guidance. Q4 earnings summary impacts financial performance and investor sentiment moderately.
26 Feb
Akebia Therapeutics Inc (AKBA) highlighted strong revenue growth in its Q4 2025 earnings call amidst ongoing challenges. Strong revenue growth in Q4 2025 earnings call represents a major positive shift in financial performance and investor sentiment for AKBA.
Akebia Therapeutics (AKBA) Q4 2025 earnings call transcript released, covering financial results, operations, and forward-looking statements. Q4 earnings call transcript discloses financial performance, guidance, and strategic updates with potential to significantly sway investor sentiment and stock trajectory.
Akebia Therapeutics released Q4 earnings call highlights covering financial results, Vafseo commercial launch progress, pipeline advancements, and 2024 guidance. Q4 earnings highlights detail financial performance, product commercialization, and strategic outlook poised to significantly influence stock trajectory and investor sentiment.
Akebia Therapeutics (AKBA) released its Q4 earnings snapshot. Q4 earnings snapshots significantly impact AKBA's financial performance and investor sentiment.
Akebia Therapeutics reported fourth quarter and full-year 2025 financial results, including commercial updates and pipeline highlights. Annual financial results combined with pipeline highlights signal potential shifts in commercial performance and development trajectory for AKBA.
12 Feb
Akebia Therapeutics highlighted its VAFSEO dialysis initiative, the TIW dosing plan, and advancements in its rare kidney disease pipeline during a recent summit. The company is focusing on innovative treatment options and strategic developments to enhance its market position in the renal therapeutics sector. The emphasis on strategic initiatives and product development in the renal space is likely to significantly impact Akebia's future performance and market positioning.
7 Feb
Akebia Therapeutics, Inc. is experiencing a shift in narrative following a recent valuation reset. The company has faced challenges in its market positioning and financial performance, prompting analysts to reassess its future prospects. This reevaluation comes amid ongoing developments in its product pipeline and competitive landscape, which could influence investor sentiment and market dynamics moving forward. The valuation reset indicates a moderately noticeable influence on Akebia's financial performance and market positioning.
12 Jan
Akebia Therapeutics, Inc. announced corporate updates and provided an outlook for its pipeline through 2026. The company highlighted advancements in its product development and strategic initiatives aimed at enhancing its market position. Key milestones and expected timelines for upcoming clinical trials were also discussed, indicating a proactive approach to addressing unmet medical needs. Significant product developments and strategic initiatives are expected to impact the company's future performance and market positioning.